Simultaneous assessment of PSA secretion and surface markers such as PSMA allows for the development of an improved composite biomarker, which in combination with the molecular characterization could enhance patient stratification, treatment monitoring, and personalized therapy selection in prostate cancer. This evidence concerns the gene FOLH1 and prostate carcinoma.